Robin Swartz serves as the Chief Operating Officer at Voyager Therapeutics Inc., a position she has held since joining the company. With a robust background in the biotechnology and pharmaceutical industries, Swartz has been instrumental in steering Voyager Therapeutics toward its mission of developing gene therapies for severe neurological diseases. Her role encompasses overseeing the company's operational strategies, ensuring efficient execution of clinical development programs, and fostering collaborations that enhance the company's research and development capabilities. Before joining Voyager Therapeutics, Swartz held several high-level positions at notable biotech firms. She has a proven track record of leading cross-functional teams and driving the successful advancement of therapeutic programs from early-stage research through to clinical trials. Her strategic vision and operational expertise have been key to her achievements, including the development of innovative treatments that have reached significant milestones in clinical development. Swartz's contributions to the field have earned her recognition as a leader in the biotechnology sector. At Voyager Therapeutics, Swartz continues to play a pivotal role in shaping the company's future. Her leadership is crucial in navigating the complex landscape of gene therapy development, from optimizing internal processes to expanding the company's portfolio through strategic partnerships. Under her guidance, Voyager Therapeutics is well-positioned to bring transformative treatments to patients suffering from debilitating neurological conditions.